Curcumin modulates miR-19/PTEN/AKT/p53 axis to suppress bisphenol A-induced MCF-7 breast cancer cell proliferation

Phytotherapy Research

Volumn 28, Issue 10, 2014, Pages 1553-1560

  Li, Xiaoting ^a   Xie, Wei ^a   Xie, Chunfeng ^a   Huang, Cong ^a   Zhu, Jianyun ^a   Liang, Zhaofeng ^a   Deng, Feifei ^a   Zhu, Mingming ^a   Zhu, Weiwei ^a   Wu, Rui ^a   Wu, Jieshu ^a   Geng, Shanshan ^a   Zhong, Caiyun ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

bisphenol A; curcumin; inhibition; MCF 7 breast cancer cells; miR 19; proliferation

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; CURCUMIN; CYCLINE; ESTROGEN RECEPTOR; MICRORNA; MICRORNA 19A; MICRORNA 19B; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG; BENZHYDRYL DERIVATIVE; MIRN19 MICRORNA, HUMAN; PHENOL DERIVATIVE; PTEN PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MCF 7 CELL LINE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; BREAST TUMOR; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; METABOLISM; SIGNAL TRANSDUCTION;

BENZHYDRYL COMPOUNDS; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; CURCUMIN; FEMALE; HUMANS; MCF-7 CELLS; MICRORNAS; PHENOLS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84908500692     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5167     Document Type: Article

References (39)

1. Bartel DP,. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281 - 297.
2. Birnbaum LS, Fenton SE,. 2003. Cancer and developmental exposure to endocrine disruptors. Environ Health Perspect 111: 389 - 394.
3. Calin GA, Sevignani C, Dumitru CD, et al. 2004. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 101: 2999 - 3004.
4. Carthew RW, Sontheimer EJ,. 2009. Origins and mechanisms of miRNAs and siRNAs. Cell 136: 642 - 655.
5. Chandarlapaty S, Sakr RA, Giri D, et al. 2012. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin Cancer Res 18: 6784 - 6791.
6. Comer FI, Parent CA,. 2002. PI 3-kinases and PTEN: how opposites chemoattract. Cell 109: 541 - 544.
7. Cuellar TL, McManus MT,. 2005. MicroRNAs and endocrine biology. J Endocrinol 187: 327 - 332.
8. Di Cristofano A, Pandolfi PP,. 2000. The multiple roles of PTEN in tumor suppression. Cell 100: 387 - 390.
9. Fenton SE,. 2006. Endocrine-disrupting compounds and mammary gland development: early exposure and later life consequences. Endocrinology 147: S18 - 24.
10. Fernandez SV, Russo J,. 2010. Estrogen and xenoestrogens in breast cancer. Toxicol Pathol 38: 110 - 122.
11. Fontana L, Fiori ME, Albini S, et al. 2008. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One 3: e2236.
12. Goodson WH, 3rd, Luciani MG, Sayeed SA, Jaffee IM, Moore DH, 2nd, Dairkee SH,. 2011. Activation of the mTOR pathway by low levels of xenoestrogens in breast epithelial cells from high-risk women. Carcinogenesis 32: 1724 - 1733.
13. Guo SL, Ye H, Teng Y, et al. 2013. Akt-p53-miR-365-cyclin D1/cdc25A axis contributes to gastric tumorigenesis induced by PTEN deficiency. Nat Commun 4: 2544 - 3544.
14. Jenkins S, Raghuraman N, Eltoum I, Carpenter M, Russo J, Lamartiniere CA,. 2009. Oral exposure to bisphenol a increases dimethylbenzanthracene-induced mammary cancer in rats. Environ Health Perspect 117: 910 - 915.
15. Kang JH, Kondo F, Katayama Y,. 2006. Human exposure to bisphenol A. Toxicology 226: 79 - 89.
16. Keri RA, Ho SM, Hunt PA, Knudsen KE, Soto AM, Prins GS,. 2007. An evaluation of evidence for the carcinogenic activity of bisphenol A. Reprod Toxicol 24: 240 - 252.
17. Kim K, Chadalapaka G, Lee SO, et al. 2012. Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer. Oncogene 31: 1034 - 1044.
18. Knobbe CB, Lapin V, Suzuki A, Mak TW,. 2008. The roles of PTEN in development, physiology and tumorigenesis in mouse models: a tissue-by-tissue survey. Oncogene 27: 5398 - 5415.
19. Lee HR, Hwang KA, Park MA, Yi BR, Jeung EB, Choi KC,. 2012. Treatment with bisphenol A and methoxychlor results in the growth of human breast cancer cells and alteration of the expression of cell cycle-related genes, cyclin D1 and p21, via an estrogen receptor-dependent signaling pathway. Int J Mol Med 29: 883 - 890.
20. Li Q, Lozano G,. 2013. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res 19: 34 - 41.
21. Lopez-Knowles E, O'Toole SA, McNeil CM, et al. 2010. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 126: 1121 - 1131.
22. Mu P, Han YC, Betel D, et al. 2009. Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev 23: 2806 - 2811.
23. Mudduluru G, George-William JN, Muppala S, et al. 2011. Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer. Biosci Rep 31: 185 - 197.
24. Nana-Sinkam SP, Croce CM,. 2011. MicroRNAs as therapeutic targets in cancer. Transl Res 157: 216 - 225.
25. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT,. 2005. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435: 839 - 843.
26. Olive V, Bennett MJ, Walker JC, et al. 2009. miR-19 is a key oncogenic component of mir-17-92. Genes Dev 23: 2839 - 2849.
27. Olive V, Li Q, He L,. 2013. mir-17-92: a polycistronic oncomir with pleiotropic functions. Immunol Rev 253: 158 - 166.
28. Ptak A, Gregoraszczuk EL,. 2012. Bisphenol A induces leptin receptor expression, creating more binding sites for leptin, and activates the JAK/Stat, MAPK/ERK and PI3K/Akt signalling pathways in human ovarian cancer cell. Toxicol Lett 210: 332 - 337.
29. Richter CA, Birnbaum LS, Farabollini F, et al. 2007. In vivo effects of bisphenol A in laboratory rodent studies. Reprod Toxicol 24: 199 - 224.
30. Rossi DJ, Weissman IL,. 2006. Pten, tumorigenesis, and stem cell self-renewal. Cell 125: 229 - 231.
31. Sevignani C, Calin GA, Siracusa LD, Croce CM,. 2006. Mammalian microRNAs: a small world for fine-tuning gene expression. Mamm Genome 17: 189 - 202.
32. Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R,. 2008. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther 7: 464 - 473.
33. Tsuda H, Naito A, Kim CK, Fukamachi K, Nomoto H, Moore MA,. 2003. Carcinogenesis and its modification by environmental endocrine disruptors: in vivo experimental and epidemiological findings. Jpn J Clin Oncol 33: 259 - 270.
34. Ventura A, Jacks T,. 2009. MicroRNAs and cancer: short RNAs go a long way. Cell 136: 586 - 591.
35. Wade M, Li YC, Wahl GM,. 2012. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 13: 83 - 96.
36. Wang Q, Li YC, Wang J, et al. 2008. miR-17-92 cluster accelerates adipocyte differentiation by negatively regulating tumor-suppressor Rb2/p130. Proc Natl Acad Sci U S A 105: 2889 - 2894.
37. Yang J, Cao Y, Sun J, Zhang Y,. 2010. Curcumin reduces the expression of Bcl-2 by upregulating miR-15a and miR-16 in MCF-7 cells. Med Oncol 27: 1114 - 1118.
38. Zhang J, Du Y, Wu C, et al. 2010. Curcumin promotes apoptosis in human lung adenocarcinoma cells through miR-186∗ signaling pathway. Oncol Rep 24: 1217 - 1223.
39. Zhang W, Bai W,. 2013. MiR-21 suppresses the anticancer activities of curcumin by targeting PTEN gene in human non-small cell lung cancer A549 cells. Clin Transl Oncol. DOI 10.1007/s12094-013-1135-9